Open AccessEffects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease
Author(s) -
Richard Haynes,
Parminder Judge,
Natalie Staplin,
William G. Herrington,
Benjamin C. Storey,
Angelyn Bethel,
Louise Bowman,
Nigel J. Brunskill,
Paul Cockwell,
Michael Hill,
Philip A. Kalra,
John J.V. McMurray,
Maarten W. Taal,
David C. Wheeler,
Martin J Landray,
Colin Baigent
Publication year - 2018
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.118.034818
Subject(s) - medicine , irbesartan , valsartan , sacubitril , sacubitril, valsartan , renal function , ejection fraction , urology , creatinine , kidney disease , albuminuria , cardiology , heart failure , blood pressure
Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced ejection fraction, but its effects on kidney function and cardiac biomarkers in people with moderate to severe chronic kidney disease are unknown.